Familial and Hereditary Syndromes in Renal Cell Cancer

  • Mark Wayne Ball
  • Peter A. PintoEmail author


Management of patients with hereditary kidney cancer presents a unique challenge for the urologic surgeon, as patients are often at risk for multiple, bilateral renal surgeries. An understanding of the genetic basis of kidney cancer has led to distinct treatment paradigms in both the surgical management of localized disease and the treatment of advanced disease with systemic therapy. Minimizing the number of interventions and subsequent renal compromise, while maximizing oncologic efficacy, is critical in treating these patients. This chapter reviews the genetics of hereditary kidney cancer with a special emphasis on the translation of genetic insights into contemporary management approaches.


Renal cell carcinoma Genetics Genomics Clear cell Papillary Chromophobe Familial Sporadic Translocation 


  1. 1.
    Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.CrossRefGoogle Scholar
  2. 2.
    Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22(11):2089–100.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRefGoogle Scholar
  4. 4.
    Kletscher BA, Qian J, Bostwick DG, Andrews PE, Zincke H. Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol. 1995;153(3 Pt 2):904–6.PubMedGoogle Scholar
  5. 5.
    Whang M, O'Toole K, Bixon R, Brunetti J, Ikeguchi E, Olsson CA, et al. The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J Urol. 1995;154(3):968–70; discussion 70–1.CrossRefPubMedGoogle Scholar
  6. 6.
    Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, Einarsson GV, Jonsdottir GM, Kristjansson K, et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer. 2002;100(4):476–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin N Am. 2012;39:133–48.CrossRefGoogle Scholar
  8. 8.
    Ball MW, Singer EA, Srinivasan R. Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Curr Opin Oncol. 2017;29(3):201–9.CrossRefGoogle Scholar
  9. 9.
    Nielsen SM, Rhodes L, Blanco I, Chung WK, Eng C, Maher ER, et al. Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol. 2016;34(18):2172–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Latif F, Tory K, Gnarra JR, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Tory K, Brauch H, Linehan WM, Barba D, Oldfield E, Filling-Katz M, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst. 1989;81:1097–101.CrossRefPubMedGoogle Scholar
  12. 12.
    Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002;1(5):459–68.CrossRefPubMedGoogle Scholar
  13. 13.
    Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 1998;26(1):256–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–37.PubMedGoogle Scholar
  15. 15.
    Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67.CrossRefPubMedGoogle Scholar
  16. 16.
    Poston CD, Jaffe GS, Lubensky IA, Solomon D, Zbar B, Linehan WM, et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol. 1995;153(1):22–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Choyke PL, Filling-Katz MR, Shawker TH, Gorin MB, Travis WD, Chang R, et al. von Hippel-Lindau disease: radiologic screening for visceral manifestations. Radiology. 1990;174(3 Pt 1):815–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172(1):63–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Singer EA, Vourganti S, Lin KY, Gupta GN, Pinto PA, Rastinehad AR, et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of follow-up. J Urol. 2012;188(6):2084–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Zbar B, Tory K, Merino MJ, Schmidt LS, Glenn GM, Choyke P, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151(3):561–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Schmidt LS, Duh FM, Chen F, Kishida T, Glenn GM, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73.CrossRefPubMedGoogle Scholar
  22. 22.
    Schmidt LS, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58(8):1719–22.PubMedGoogle Scholar
  23. 23.
    Schmidt LS, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18(14):2343–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Lubensky IA, Schmidt LS, Zhuang Z, Weirich G, Pack S, Zambrano N, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155(2):517–26.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ornstein DK, Lubensky IA, Venzon D, Zbar B, Linehan WM, Walther MM. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol. 2000;163(2):431–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Zbar B, Glenn GM, Lubensky IA, Choyke P, Magnusson G, Bergerheim U, et al. Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol. 1995;153(3, Supplement 1):907–12.PubMedGoogle Scholar
  27. 27.
    Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, et al. Early onset Hereditary Papillary Renal Carcinoma: germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene. J Urol. 2004;172(4, Part 1 Of 2):1256–61.CrossRefPubMedGoogle Scholar
  28. 28.
    Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol. 1977;113(12):1674–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Zbar B, Alvord WG, Glenn GM, Turner M, Pavlovich CP, Schmidt LS, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11(4):393–400.PubMedGoogle Scholar
  30. 30.
    Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dub‚ syndrome. Am J Hum Genet. 2005;76(6):1023–33.Google Scholar
  31. 31.
    Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke CD, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45(6):321–31.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Schmidt LS, Linehan WM. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat Rev Urol. 2015;12(10):558–69.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, et al. Renal tumors in the Birt-Hogg-Dub‚ syndrome. Am J Surg Pathol. 2002;26(12):1542–52.Google Scholar
  34. 34.
    Leung C, Pan S, Shuch B. Management of renal cell carcinoma in young patients and patients with hereditary syndromes. Curr Opin Urol. 2016;26(5):396–404.CrossRefPubMedGoogle Scholar
  35. 35.
    Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98(6):3387–2.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Merino MJ, Torres-Cabala C, Pinto PA, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31(10):1578–85.CrossRefPubMedGoogle Scholar
  37. 37.
    Grubb RL III, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177(6):2074–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis. 2014;7:253–60.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73(1):95–106.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43(1):18–27.CrossRefPubMedGoogle Scholar
  41. 41.
    Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406–10.CrossRefPubMedGoogle Scholar
  42. 42.
    Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am. 2012;39(2):133–48. v.CrossRefPubMedGoogle Scholar
  43. 43.
    Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol. 2012;
  44. 44.
    Gill AJ, Hes O, Papathomas T, Sedivcova M, Tan PH, Agaimy A, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38(12):1588–602.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285–94.CrossRefPubMedGoogle Scholar
  46. 46.
    Farley MN, Schmidt LS, Mester JL, Pena-Llopis S, Pavia-Jimenez A, Christie A, et al. Germline BAP1 mutation predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res. 2013;11:1061.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d'Enghien C, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92(6):974–80.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol. 2016;71(4):606–17.CrossRefPubMedGoogle Scholar
  49. 49.
    Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11(8):465–75.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32(2):103–13.CrossRefPubMedGoogle Scholar
  51. 51.
    Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480(7375):94–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Gorin MA, Ball MW, Pierorazio PM, Argani P, Allaf ME. Partial nephrectomy for the treatment of translocation renal cell carcinoma. Clin Genitourin Cancer. 2015;13(3):e199–201.CrossRefPubMedGoogle Scholar
  53. 53.
    Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–56.CrossRefPubMedGoogle Scholar
  54. 54.
    Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149(4):1–8.Google Scholar
  55. 55.
    Kothary N, Soulen MC, Clark TW, Wein AJ, Shlansky-Goldberg RD, Crino PB, et al. Renal angiomyolipoma: long-term results after arterial embolization. J Vasc Interv Radiol. 2005;16(1):45–50.CrossRefPubMedGoogle Scholar
  56. 56.
    Cristescu M, Abel EJ, Wells S, Ziemlewicz TJ, Hedican SP, Lubner MG, et al. Percutaneous microwave ablation of renal angiomyolipomas. Cardiovasc Intervent Radiol. 2016;39(3):433–40.CrossRefPubMedGoogle Scholar
  57. 57.
    Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140–51.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301:592–5.CrossRefPubMedGoogle Scholar
  59. 59.
    van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P, et al. Renal cell cancer: chromosome 3 translocations as risk factors. J Natl Cancer Inst. 1999;91(13):1159–60.CrossRefPubMedGoogle Scholar
  60. 60.
    Rodriguez-Perales S, Melendez B, Gribble SM, Valle L, Carter NP, Santamaria I, et al. Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. Hum Mol Genet. 2004;13(9):983–90.CrossRefPubMedGoogle Scholar
  61. 61.
    Schmidt LS, Li F, Brown RS, Berg S, Chen F, Wei MH, et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am. 1995;1(3):191–5.PubMedGoogle Scholar
  62. 62.
    Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund G, et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol. 1995;153(6):1812–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon D, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161(5):1475–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Pavlovich CP, Grubb RL 3rd, Hurley K, Glenn GM, Toro J, Schmidt LS, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol. 2005;173(5):1482–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998;83(10):2208–16.CrossRefPubMedGoogle Scholar
  66. 66.
    Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149(4):1201–8.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Wunderlich H, Schlichter A, Zermann D, Reichelt O, Kosmehl H, Schubert J. Multifocality in renal cell carcinoma: a bilateral event? Urol Int. 1999;63(3):160–3.CrossRefPubMedGoogle Scholar
  68. 68.
    Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, et al. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int. 2007;100(1):21–5.CrossRefPubMedGoogle Scholar
  69. 69.
    Calne RY. Treatment of bilateral hypernephromas by nephrectomy, excision of tumour, and autotransplantation. Report of three cases. Lancet. 1973;2(7839):1164–7.CrossRefPubMedGoogle Scholar
  70. 70.
    Clark JE. Transplantation for bilateral renal tumors. JAMA. 1970;211(8):1379.CrossRefPubMedGoogle Scholar
  71. 71.
    Jochimsen PR, Braunstein PM, Najarian JS. Renal allotransplantation for bilateral renal tumors. JAMA. 1969;210(9):1721–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Fadahunsi AT, Sanford T, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol. 2011;185(1):49–53.CrossRefPubMedGoogle Scholar
  73. 73.
    Walther MM, Choyke PL, Weiss G, Manolatos C, Long J, Reiter R, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol. 1995;153(3 Pt 2):913–6.PubMedGoogle Scholar
  74. 74.
    Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995;154(6):2010–4; discussion 4–5.CrossRefPubMedGoogle Scholar
  75. 75.
    Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, et al. Surveillance following nephron-sparing surgery: an assessment of recurrence patterns and surveillance costs. Urology. 2015;86(2):321–6.CrossRefPubMedGoogle Scholar
  76. 76.
    Bratslavsky G, Liu JJ, Johnson AD, Sudarshan S, Choyke PL, Linehan WM, et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol. 2008;179(1):67–70.CrossRefPubMedGoogle Scholar
  77. 77.
    Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of repeat partial nephrectomy. J Urol. 2008;180(1):89–93; discussion.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Liu NW, Khurana K, Sudarshan S, Pinto PA, Linehan WM, Bratslavsky G. Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes. J Urol. 2010;183(5):1719–24.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Maurice MJ, Ramirez D, Nelson R, Caputo P, Kara O, Malkoc E, et al. Multiple tumor excisions in ipsilateral kidney increase complications after partial nephrectomy. J Endourol. 2016;30:1200.CrossRefPubMedGoogle Scholar
  80. 80.
    Minervini A, Serni S, Giubilei G, Lanzi F, Vittori G, Lapini A, et al. Multiple ipsilateral renal tumors: retrospective analysis of surgical and oncological results of tumor enucleation vs radical nephrectomy. Eur J Surg Oncol. 2009;35(5):521–6.CrossRefPubMedGoogle Scholar
  81. 81.
    Shuch B, Linehan WM, Bratslavsky G. Repeat partial nephrectomy: surgical, functional and oncological outcomes. Curr Opin Urol. 2011;21(5):368–75.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Carini M, Minervini A, Masieri L, Lapini A, Serni S. Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol. 2006;50(6):1263–8; discussion 9–71.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Center for Cancer Research, NCI, NIH, Urologic Oncology BranchBethesdaUSA
  2. 2.NIH Clinical Center, Urologic Oncology BranchBethesdaUSA

Personalised recommendations